<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KCNQ2 — Potassium Voltage-Gated Channel Subfamily Q Member 2</th>
</tr>
<tr> [@gu2015]
<td class="label">Symbol</td> [@jones2001]
<td><strong>KCNQ2</strong></td> [@singh1998]
</tr> [@weckhuysen2012]
<tr> [@gunthorpe2012]
<td class="label">Full Name</td>
<td>Potassium Voltage-Gated Channel Subfamily Q Member 2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>20q13.33</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/3785" target="_blank">3785</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155085" target="_blank">ENSG00000155085</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/121200" target="_blank">121200</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/O43526" target="_blank">O43526</a></td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Kv7.2 (Potassium voltage-gated channel subfamily Q member 2)</td>
</tr>
<tr>
<td class="label">Channel Type</td>
<td>Voltage-gated potassium channel (K+)</td>
</tr>
<tr>
<td class="label">Ion Selectivity</td>
<td>K+ > Na+</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>[Hippocampus](/brain-regions/hippocampus), Cerebral [cortex](/brain-regions/cortex), Basal ganglia, Cerebellum</td>
</tr>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KCNQ2 — Potassium Voltage-Gated Channel Subfamily Q Member 2</th>
</tr>
<tr> [@gu2015]
<td class="label">Symbol</td> [@jones2001]
<td><strong>KCNQ2</strong></td> [@singh1998]
</tr> [@weckhuysen2012]
<tr> [@gunthorpe2012]
<td class="label">Full Name</td>
<td>Potassium Voltage-Gated Channel Subfamily Q Member 2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>20q13.33</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/3785" target="_blank">3785</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155085" target="_blank">ENSG00000155085</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/121200" target="_blank">121200</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/O43526" target="_blank">O43526</a></td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Kv7.2 (Potassium voltage-gated channel subfamily Q member 2)</td>
</tr>
<tr>
<td class="label">Channel Type</td>
<td>Voltage-gated potassium channel (K+)</td>
</tr>
<tr>
<td class="label">Ion Selectivity</td>
<td>K+ > Na+</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>[Hippocampus](/brain-regions/hippocampus), Cerebral [cortex](/brain-regions/cortex), Basal ganglia, Cerebellum</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Benign Familial Neonatal Seizures (BFNS), Epilepsy of Infancy with Migrating Focal Seizures, Developmental Delay, Intellectual Disability</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/epilepsy" style="color:#ef9a9a">Epilepsy</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">44 edges</a></td>
</tr>
</table>
Kcnq2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KCNQ2 (Potassium Voltage-Gated Channel Subfamily Q Member 2) is a gene located on chromosome 20q13.33 that encodes the Kv7.2 voltage-gated potassium channel. This channel is a critical regulator of neuronal excitability, conducting the M-current (M for muscarinic), a slow-activating potassium current that dampens neuronal firing. KCNQ2 mutations are the primary cause of benign familial neonatal seizures (BFNS), a self-limiting epilepsy syndrome in newborns. The gene is catalogued as NCBI Gene ID [3785](https://www.ncbi.nlm.nih.gov/gene/3785) and OMIM [121200](https://omim.org/entry/121200).
The Kv7.2 protein is a member of the KCNQ (KQT-like) family of potassium channels. Each channel consists of four Kv7.2 subunits, each containing six transmembrane segments (S1-S6). The S4 segment functions as the voltage sensor, while the S5-S6 pore domain forms the ion conduction pathway [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654242/). Unlike classical voltage-gated potassium channels (Kv channels), Kv7.2 has relatively slow activation and deactivation kinetics, making it ideally suited for its role in modulating neuronal excitability.
Kv7.2 channels conduct the M-current (M-current), a distinctive potassium current that is inhibited by muscarinic [acetylcholine](/entities/acetylcholine) receptor activation. The M-current operates near the resting membrane potential and provides a voltage-dependent brake on neuronal firing. When [neurons](/entities/neurons) become depolarized, Kv7.2 channels slowly activate, producing outward K+ current that counteracts depolarization and limits action potential firing frequency [2](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858074/). This negative feedback mechanism is crucial for preventing excessive neuronal activity.
Kv7.2 typically co-assembles with Kv7.3 (KCNQ3) to form heterotetrameric channels with distinct properties. The Kv7.2/Kv7.3 heteromer is the predominant M-channel in the brain, exhibiting greater current amplitude and more hyperpolarized voltage dependence than homomeric Kv7.2 channels [3](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744994/). This assembly is essential for proper M-current function in neurons.
The M-current plays a fundamental role in setting resting membrane potential and regulating subthreshold excitability. Kv7.2/Kv7.3 channels are open at resting membrane potentials (-60 to -70 mV), providing steady outward K+ current that stabilizes the membrane. This "leak-like" behavior distinguishes the M-current from rapidly inactivating sodium currents [4](https://www.ncbi.nlm.nih.gov/books/NBK10828/).
By providing a voltage-dependent dampening mechanism, Kv7.2 channels limit the frequency of action potential firing. During sustained depolarization, M-current activation increases proportionally, creating a negative feedback loop that prevents runaway excitation. This property is essential for maintaining proper firing patterns in cortical and hippocampal neurons [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362746/).
Kv7.2 channels are targets of neuromodulatory systems. Muscarinic acetylcholine receptor activation (via Gq protein signaling) inhibits M-current, producing depolarization and increased neuronal excitability. This mechanism underlies the arousal-promoting effects of acetylcholine in the forebrain. Conversely, activation of serotonin receptors and other Gq-coupled receptors can also modulate M-current [6](https://pubmed.ncbi.nlm.nih.gov/12629554/).
KCNQ2 mutations cause approximately 70-80% of BFNS cases, making it one of the most common genetic causes of neonatal seizures. BFNS is characterized by seizures that begin within the first week of life and typically resolve by 4-6 months of age. The seizures are usually focal tonic or clonic and may occur in clusters. Despite the dramatic presentation, developmental outcome is typically normal, hence the "benign" designation [7](https://pubmed.ncbi.nlm.nih.gov/12427840/).
The pathophysiology involves haploinsufficiency of Kv7.2 channels, reducing M-current amplitude and causing neuronal hyperexcitability in neonatal circuits. However, compensatory mechanisms during development lead to seizure remission.
Several severe epilepsy syndromes are associated with de novo KCNQ2 mutations:
Beyond epilepsy, KCNQ2 mutations are associated with:
Retigabine (commercially known as Ezogabine) is a Kv7.2/7.3 channel opener that was approved for treating focal epilepsy. It works by stabilizing the open state of the channel, enhancing M-current and reducing neuronal excitability. However, due to limited efficacy and side effects, it has been discontinued in many regions [9](https://pubmed.ncbi.nlm.nih.gov/21859149/).
Current research focuses on developing:
The study of Kcnq2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving KCNQ2 Gene discovered through SciDEX knowledge graph analysis: